Skip to main content

Retail Clinics

  • Tris seeks FDA OK for allergy treatment for kids

    MONMOUTH JUNCTION, N.J. — The Food and Drug Administration has accepted a regulatory approval application from Tris Pharma for a drug to treat allergies in children ages 2 years and older, Tris said Wednesday.

    Tris said that if approved, its carbinoxamine extended-release oral suspension would provide an alternative to currently available immediate-release formulations.

  • UltiMed introduces 50-count needles offering for diabetes patients

    ST. PAUL, Minn. — UltiMed is offering 50-count pen needles for patients with diabetes, the company announced.

    The company said the needles would give diabetes patients a high-quality and cost-effective option for their pen needle supplies. Before, pen needles were dispensed in quantities of 100.

    UltiMed said its needles, manufactured in its De Smet, S.D., factory, are the only ones assembled in the United States.

  • HealthOneMed debuts Dispense-a-Pill

    LEHIGH VALLEY, Pa. — HealthOneMed has launched a device that combines the abilities of pillboxes, reminders, dispensers and medication alerts into one.

  • 3M debuts Cavilon antifungal cream

    ST. PAUL, Minn. — 3M's skin and wound care division has launched an easy-to-apply cream that is designed to relieve skin discomforts caused by fungal infections.

    New Cavilon antifungal cream, which is available in 2-oz. and 5-oz. tubes, is enriched with water-repelling ingredients, including 2% miconazole nitrate, an active ingredient that has been clinically proven to treat tinea corporis (ringworm), tinea pedis (athlete’s foot) and tinea cruris (jock itch), 3M said. The product also is approved for use on fungal infections caused by Candida albicans.

  • Wellesse introduces digestive health supplement

    FERNDALE, Wash. — Wellesse earlier this week introduced its Digestive 3-in-1 Health, a liquid supplement that promotes healthy digestion and regularity, soothes the stomach and helps the body resist occasional imbalance.

    "Most people who indulge pay for it with uncomfortable, embarrassing or even tiring digestive symptoms on a regular basis," stated registered dietitian Marie Spano, speaking on behalf of Wellesse.

  • Oral contraceptive Emoquette wins FDA approval

    HUNTSVILLE, Ala. — A subsidiary of Endo Pharmaceuticals has won approval from the Food and Drug Administration for an oral contraceptive.

    Qualitest Pharmaceuticals announced Friday the approval of Emoquette (desogestrel and ethinyl estradiol) tablets in the 0.15-mg/0.03-mg strength.

    The drug is a generic version of Johnson & Johnson’s Ortho-Cept.

  • Manhattan Institute studies state of clinics

    NEW YORK — The Manhattan Institute has come up with a novel idea to help New York state slash its healthcare costs by a hefty $350 million by 2020: Expand access to retail health clinics.

    Sounds simple enough, right? Think again.

  • FDA lifts liver injury risk boxed warning from Gilead's Letairis

    FOSTER CITY, Calif. — Gilead on Friday announced that the Food and Drug Administration has removed a boxed warning about a possible liver injury risk caused by the drug maker's hypertension treatment.

    Gilead said the FDA approved a change to the prescribing information for Letairis (ambrisentan 5-mg and 10-mg tablets), the company’s once-daily treatment of pulmonary arterial hypertension.

X
This ad will auto-close in 10 seconds